Table 2.

Summary of ongoing and published trials of immunotherapy in DTC.

Drug	Trial	Number of patients	Study population	Efficacy results	Reference
Atezolizumab + cabozantinib	COSMIC-021 (NCT03170960), Phase Ib	31	Treatment-naïve, locally advanced, metastatic and/or progressive RR-DTCs	42% PR, 55% SD Median PFS: 15.2 months	Taylor et al. (104)
Durvalumab + tremelimumab	NCT03753919, phase II	N/A	Locally advanced or metastatic RR-DTC	Ongoing	N/A
Ipilimumab+ nivolumab	NCT03246958, Phase II	32	Metastatic RR-DTC with progression ≤ 13 months prior to enrollment	Interim results: 9% PR, 44% SD Median PFS: 4.9months	Lorch et al. (105)
Ipilimumab/nivolumab + cabozantinib	NCT03914300, Phase II	11	Locally advanced or metastatic RR-DTCs that have progressed on one previous anti-VEGFR therapy	Interim results: 18% PR, 54% SD Median PFS: 9 months	Konda et al. (106)
Nivolumab + encorafenib/binimetinib	NCT04061980, Phase II	N/A	Metastatic, BRAF V600E mutant RR-DTC	Ongoing	N/A
Pembrolizumab (Single agent)	KEYNOTE-028 (NCT02054806), Phase Ib	22	Locally advanced or metastatic DTC	PR+SD for at least 6 mos: 50% Median PFS: 7 months	Mehnert et al. (100)
Pembrolizumab + lenvatinib	NCT02973997, Phase II	30	Treatment-naïve, RR-DTC with progression ≤ 14 months prior to enrollment	62% PR, 35% SD Median PFS: NR 12-month PFS: 74%	Haugen et al. (101)

Mos, months; NR, not reached; N/A, not applicable.